Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China flag China · Delayed Price · Currency is CNY
122.10
+4.70 (4.00%)
Jul 31, 2026, 3:00 PM CST

SHA:688266 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
2,0942,0312,1542,110797.051,137
Trading Asset Securities
375.58-40.5137.02248.9365.26
Cash & Short-Term Investments
2,4702,0312,1942,2471,0461,202
Cash Growth
14.79%-7.43%-2.34%114.79%-12.97%-24.86%
Accounts Receivable
204.29154.25143.63101.1488.9962.37
Other Receivables
7.5810.279.3810.8912.5112.45
Receivables
211.87164.52153.01112.03101.574.82
Inventory
192.87173.27182.86110.8598.9851.91
Other Current Assets
87.5274.1345.8550.7945.377.33
Total Current Assets
2,9622,4432,5762,5201,2921,406
Property, Plant & Equipment
522.62485.89363.43271.21247.09188.91
Long-Term Investments
---5.991010
Other Intangible Assets
24.4630.5950.0169.2791.03116.29
Long-Term Deferred Charges
3.885.9811.3916.3920.9613.03
Other Long-Term Assets
13.323.633.884.027.4811.78
Total Assets
3,5262,9693,0052,8871,6681,746
Accounts Payable
293.74244.16197.1137.73151.72118.19
Accrued Expenses
74.189.5286.2282.0267.548.22
Short-Term Debt
674.86989.05951.86795.16390.79131.81
Current Portion of Long-Term Debt
48.8642.14.9750.5650.0430.03
Current Portion of Leases
-9.0111.213.1713.6913.55
Current Income Taxes Payable
24.9313.9720.9520.6420.2918.58
Current Unearned Revenue
39.291.25--0.280.36
Other Current Liabilities
29.3838.88101.1535.8934.8820.16
Total Current Liabilities
1,1851,4281,3731,135729.19380.89
Long-Term Debt
83.58444.35-50.09-
Long-Term Leases
5.728.626.8629.4643.1848.18
Long-Term Unearned Revenue
7.688.079.211.5545.0448.05
Long-Term Deferred Tax Liabilities
-1.645.79.5813.3215.77
Other Long-Term Liabilities
523.69358.49292.4556.6--
Total Liabilities
1,8061,8891,7521,242880.82492.88
Common Stock
264.71264.71264.71264.71240240
Additional Paid-In Capital
3,1093,1093,1203,3532,2222,205
Retained Earnings
-1,640-2,280-2,117-1,979-1,700-1,243
Comprehensive Income & Other
-14.02-14.05-14.47-5.95-2.84-6.32
Total Common Equity
1,7201,0801,2541,633759.121,196
Minority Interest
---1.2611.9828.3756.76
Shareholders' Equity
1,7201,0801,2531,645787.491,253
Total Liabilities & Equity
3,5262,9693,0052,8871,6681,746
Total Debt
812.941,1331,039888.35547.8223.57
Net Cash (Debt)
1,657898.421,1551,358498.18978.32
Net Cash Growth
63.57%-22.21%-14.97%172.65%-49.08%-36.78%
Net Cash Per Share
6.253.424.365.312.084.08
Filing Date Shares Outstanding
264.24264.71264.71264.71264.49240
Total Common Shares Outstanding
264.24264.71264.71264.71240240
Working Capital
1,7771,0151,2021,385562.571,025
Book Value Per Share
6.514.084.746.173.164.98
Tangible Book Value
1,6961,0501,2041,564668.091,080
Tangible Book Value Per Share
6.423.974.555.912.784.50
Buildings
-138.34135.2641.9341.9341.21
Machinery
-158.18145.53120.48121.7496.02
Construction In Progress
-275.93123.47135.8386.6727.25